Nanomedicine in Targeted Drug Delivery: Recent Progress and Future Prospects

Amina Rahman[1]

[1]University of Dhaka, Bangladesh

Amina.rahman111@hotmail.com[1]

Abstract

Nanomedicine, the application of nanotechnology in medicine, has revolutionized targeted drug delivery by enabling precise transport of therapeutic agents to specific tissues or cells. By leveraging nanoscale carriers such as liposomes, polymeric nanoparticles, dendrimers, and inorganic nanomaterials, targeted delivery systems can improve drug bioavailability, reduce systemic toxicity, and enhance therapeutic efficacy. Recent progress in stimuli-responsive nanoparticles, surface functionalization, and multi-modal delivery platforms has expanded the potential of nanomedicine in treating cancer, cardiovascular diseases, neurological disorders, and infectious diseases. This review explores the principles of nanomedicine-based drug delivery, highlights recent advances, examines challenges in clinical translation, and outlines future directions for next-generation nanotherapeutics.

Keywords: Nanomedicine; Targeted Drug Delivery; Nanoparticles; Liposomes; Polymeric Nanocarriers; Dendrimers; Inorganic Nanomaterials

Article Number: SCHORES-JHLBS-01-003
SchoRes Journal of Health, Life, and Biomedical Sciences
Volume 1, Issue 1, December 2025
Date Published: 1 December 2025

www.schores.org

1. Introduction

Targeted drug delivery represents a cornerstone of next-generation therapeutic strategies, fundamentally reshaping how medicines interact with the human body. It emphasizes precision in directing pharmacological agents to specific cells, tissues, or organs, thereby enhancing efficacy and minimizing collateral damage to healthy tissues. Traditional drug delivery systems, such as oral or intravenous administration, often suffer from systemic dispersion, rapid metabolism, and poor bioavailability issues that not only reduce therapeutic potential but also contribute to significant side effects. In contrast, nanomedicine provides a platform to overcome these challenges through the design of nanoscale carriers capable of controlled and site-specific delivery (Allen et al., 2013).

Nanocarriers including liposomes, polymeric nanoparticles, dendrimers, carbon-based materials, metallic nanoparticles, and hybrid nanostructures offer customizable architectures for encapsulating diverse therapeutic agents such as small molecules, peptides, proteins, and nucleic acids. Their nanoscale dimensions (1–100 nm) allow them to exploit natural biological processes, such as endocytosis and transcytosis, for cellular uptake and intracellular trafficking. Moreover, surface functionalization with polyethylene glycol (PEGylation), targeting ligands, or charge-modifying groups enhances their biocompatibility, prolongs circulation time, and reduces premature immune clearance by the reticuloendothelial system (Danhier et al., 2012).

The Enhanced Permeability and Retention (EPR) effect remains a fundamental principle in passive targeting, particularly within tumor microenvironments characterized by leaky vasculature and impaired lymphatic drainage. However, passive targeting alone may not ensure sufficient selectivity; hence, active targeting strategies are increasingly employed. These involve decorating nanoparticles with ligands such as monoclonal antibodies, folic acid, aptamers, or peptides that bind specifically to overexpressed receptors on diseased cells, ensuring receptor-mediated endocytosis and precise intracellular drug delivery.

In recent years, research has advanced toward stimuli-responsive nanocarriers, which respond to specific physiological or external triggers to release their therapeutic payloads at the target site. Examples include pH-sensitive nanoparticles for tumor or lysosomal environments, redox-responsive systems that exploit elevated glutathione levels in cancer cells, and temperature- or enzyme-triggered release mechanisms that ensure precise spatiotemporal control. Moreover, magnetic, photothermal, and ultrasound-responsive nanoparticles offer non-invasive, externally regulated delivery pathways, opening new avenues for precision therapy.

The concept of theranostics the integration of therapy and diagnostics within a single nanosystem has further revolutionized nanomedicine. Theranostic nanoparticles combine imaging agents (such as quantum dots, gold nanorods, or magnetic nanoparticles) with therapeutic drugs, enabling simultaneous disease diagnosis, targeted treatment, and real-time monitoring of therapeutic outcomes. This approach aligns seamlessly with the emerging paradigm of personalized medicine, where treatments are tailored to individual patient profiles based on molecular and genetic data.

Despite these breakthroughs, translational challenges remain significant. Biological barriers such as opsonization, renal filtration, and nonspecific accumulation in the liver or spleen continue to hinder efficient biodistribution. Additionally, nanoparticle toxicity, immunogenicity, and long-term biocompatibility raise safety concerns. Manufacturing and scalability issues including reproducibility, stability, and cost-effectiveness further complicate clinical deployment. Moreover, the lack of standardized regulatory frameworks for nanomedicines contributes to delays in approval and market entry.

2. Types of Nanocarriers

Nanocarriers are broadly classified based on composition, structure, and functional properties. Liposomes are spherical vesicles composed of phospholipid bilayers capable of encapsulating both hydrophilic and hydrophobic drugs. They were among the first nanocarriers translated into clinical practice, with liposomal formulations of doxorubicin demonstrating reduced systemic toxicity and improved accumulation in tumors. Polymeric nanoparticles, typically constructed from biodegradable polymers like poly(lactic-co-glycolic acid) (PLGA), provide controlled drug release and allow surface modification for active targeting (Danhier et al., 2012)..

Dendrimers are highly branched, monodisperse macromolecules that offer multivalent surfaces for drug conjugation or ligand attachment. Their size, charge, and architecture can be precisely controlled, enabling intracellular delivery of therapeutics. Lipid nanoparticles, including those used in mRNA vaccine delivery, are composed of lipid bilayers or lipid-based matrices and excel in nucleic acid delivery due to their biocompatibility and efficient cellular uptake. Inorganic nanoparticles, such as gold, silica, or iron oxide, offer unique functionalities, including imaging enhancement, photothermal therapy, and magnetic targeting, allowing integration of diagnostics and therapy within a single platform (Hou et al., 2021).



Figure 1: Types of Nanocarriers

3. Literature Review

The evolution of nanomedicine in targeted drug delivery has been driven by advances in material science, surface engineering, and biological understanding. Early formulations, such as liposomal doxorubicin, demonstrated that encapsulating chemotherapeutics in nanoparticles can reduce systemic toxicity and enhance accumulation in tumors (Allen & Cullis, 2013). Polymeric nanoparticles, composed of biodegradable polymers like PLGA, enabled controlled drug release and surface functionalization for active targeting, providing greater flexibility in design (Danhier et al., 2012).

Dendrimers, with their highly branched architecture, allow multivalent drug conjugation and precise control over size and charge, facilitating intracellular delivery. Inorganic nanoparticles, including gold, silica, and iron oxide, offer additional functionalities such as imaging contrast enhancement, photothermal therapy, and magnetic targeting (Shi et al., 2017).

Recent studies have emphasized stimuli-responsive nanocarriers that release therapeutic agents in response to local environmental cues. For example, pH-sensitive nanoparticles exploit the acidic microenvironment of tumors or inflamed tissues, while redox-sensitive carriers respond to elevated glutathione levels within cells (Bobo et al., 2016). Active targeting strategies employ ligands that bind selectively to overexpressed receptors on diseased cells, increasing uptake and therapeutic efficacy. Multifunctional platforms, integrating therapeutic and diagnostic capabilities, enable simultaneous imaging and treatment, exemplifying the concept of theranostics (Rosenblum et al., 2018).

Nanomedicine has also expanded into gene delivery, RNA interference, and CRISPR-based therapeutics. Lipid nanoparticles have been instrumental in delivering mRNA vaccines, demonstrating the clinical feasibility of nucleic acid-based nanotherapies (Hou et al., 2021, Tanaka, 2022).. These advances highlight the versatility and growing impact of nanomedicine in precision therapy and personalized medicine.

4. Methodology

The development of nanomedicine-based targeted delivery systems involves several critical steps. First, carrier design is guided by the therapeutic cargo, disease target, and desired pharmacokinetics. Parameters such as size, shape, surface charge, and biodegradability are optimized to enhance circulation time and tissue penetration. Next, surface functionalization is performed to enable targeting. Ligands such as antibodies, peptides, aptamers, or small molecules are conjugated to nanoparticle surfaces to bind specific receptors on target cells. PEGylation (Danhier et al., 2012) is often employed to reduce immune clearance and improve systemic circulation. Drug loading and encapsulation efficiency are evaluated to ensure adequate delivery doses. Hydrophilic and hydrophobic drugs require different encapsulation strategies, including adsorption, covalent conjugation, or entrapment within polymeric or lipid matrices.In vitro characterization assesses physicochemical properties (size, charge, morphology), drug release profiles, stability, and cytotoxicity. Cellular uptake, endosomal escape, and targeting efficiency are examined using fluorescence microscopy, flow cytometry, or live-cell imaging. In vivo evaluation in animal models is essential to study biodistribution, pharmacokinetics, efficacy, and safety. Imaging techniques such as MRI, PET, and fluorescence imaging are often employed for real-time tracking of nanoparticles. Feedback from these studies informs iterative optimization of carrier design, targeting strategies, and dosing regimens.Finally, scaling up for clinical translation requires reproducible manufacturing, rigorous quality control, and compliance with regulatory guidelines, including GMP standards (Bobo et al., 2016).

5. Mechanisms and Targeting Strategies

Nanocarriers deliver therapeutics to target cells through both passive and active mechanisms. Passive targeting exploits the EPR effect, wherein nanoparticles preferentially accumulate in tissues with leaky vasculature, such as tumors or inflamed tissues. Active targeting involves surface functionalization with ligands that bind selectively to receptors overexpressed on diseased cells, promoting receptor-mediated endocytosis and enhanced intracellular delivery (Bobo et al., 2016).

Stimuli-responsive nanocarriers further improve targeting precision. pH-sensitive nanoparticles release their payload in acidic environments, characteristic of tumor microenvironments or inflamed tissues. Redox-sensitive carriers respond to high intracellular glutathione levels, releasing drugs selectively inside cells (Zhao et al, 2021). Thermo-responsive nanoparticles release therapeutics upon local heating, enabling spatial control. Multi-stimuli-responsive systems combine several triggers to further refine targeting specificity, reduce off-target effects, and enhance therapeutic outcomes (Majumder, 2021).

6. Therapeutic Applications

Nanomedicine has found extensive applications across multiple medical domains. In oncology, liposomal doxorubicin and polymeric nanoparticles enhance chemotherapeutic delivery, improving tumor accumulation while reducing systemic toxicity. Engineered nanoparticles can carry multiple drugs simultaneously, enabling combination therapies to overcome multidrug resistance. Stimuli-responsive and ligand-targeted nanocarriers further refine cancer therapy by selectively activating in tumor tissue (Bobo et al., 2016).

In cardiovascular medicine, nanoparticles have been employed to deliver anti-inflammatory drugs to atherosclerotic plaques or thrombolytic agents to occluded vessels, improving therapeutic efficacy and minimizing systemic bleeding risks. Neurological disorders benefit from nanoparticles capable of crossing the blood-brain barrier, enabling delivery of neuroprotective agents, gene therapies, or RNA interference molecules directly to affected brain regions (Tanaka, 2022).

Nanomedicine also plays a role in infectious disease management. Lipid nanoparticles delivering mRNA vaccines against SARS-CoV-2 exemplify the potential of nanocarriers to rapidly respond to emerging pathogens. In addition, targeted delivery of antibiotics using nanoparticles improves local drug concentration at infection sites, reducing systemic side effects and bacterial resistance development. Furthermore, nanoparticles are increasingly explored for gene therapy and regenerative medicine applications, including delivery of CRISPR-Cas components and growth factors for tissue repair (Hou et al., 2021).



Figure 2: Therapeutic Applications

7. Challenges

Despite remarkable progress, several challenges continue to hinder the widespread clinical translation of nanomedicine. One major obstacle is immunogenicity, whereby the body's immune system recognizes nanoparticles as foreign, triggering rapid clearance by the mononuclear phagocyte system (MPS). This not only reduces circulation time but can also provoke unintended inflammatory or hypersensitivity reactions, limiting therapeutic efficacy. Even with surface modifications such as PEGylation, immune recognition and protein corona formation remain significant barriers that can alter nanoparticle behavior in vivo.

Another critical challenge is off-target accumulation. Nanoparticles may inadvertently accumulate in organs such as the liver, spleen, and kidneys due to their size, charge, or surface properties, leading to potential toxicity or organ dysfunction. The biodistribution of nanoparticles is influenced by complex physiological factors, including blood flow, vascular permeability, and interstitial transport, making predictable targeting difficult.

Manufacturing reproducibility and scalability present additional hurdles. Nanoparticles often require precise control over size, morphology, surface chemistry, and drug loading efficiency. Small variations in these parameters can significantly impact therapeutic outcomes and safety. Scaling laboratory formulations to industrial production while maintaining consistency, quality, and cost-effectiveness remains a formidable challenge. The high cost of specialized equipment, materials, and stringent quality control processes further complicates commercial viability.

Moreover**,** regulatory approval for nanomedicine is inherently complex due to the multifunctional and novel nature of many platforms. Nanoparticles frequently combine multiple therapeutic agents, imaging components, or stimuli-responsive features, making standard safety and efficacy assessment difficult. Traditional regulatory frameworks may not adequately address the unique pharmacokinetics, biodistribution, and long-term effects of nanomaterials, necessitating new evaluation protocols and guidelines (Rosenblum et al., 2018).

To overcome these barriers, advances in biocompatible and biodegradable materials are essential to minimize immunogenicity and reduce accumulation in non-target tissues. Rational design using computational modeling and machine learning can optimize particle characteristics, predict in vivo behavior, and guide iterative development, reducing experimental inefficiency. Early collaboration with regulatory authorities is also crucial to align product design with safety standards and streamline approval processes. Additionally, the development of standardized manufacturing protocols, robust quality control measures, and cost-effective production strategies will be critical for translating nanomedicine from laboratory innovation to clinical reality. By addressing these interrelated challenges, the field can move closer to realizing the full potential of targeted nanotherapeutics for precision medicine.

8. Future Prospects

The future of nanomedicine in targeted drug delivery is poised to be driven by personalization, intelligent systems, and multifunctional platforms that integrate therapeutic and diagnostic capabilities. Patient-specific nanoparticles, designed using detailed molecular and genetic profiles, hold the potential to optimize therapeutic efficacy, minimize off-target effects, and enable truly personalized treatment regimens. Such precision design may involve tailoring particle size, surface chemistry, ligand composition, and drug payload according to individual patient characteristics, including disease stage, receptor expression patterns, and metabolic parameters.

The integration of artificial intelligence (AI) and computational modeling is expected to accelerate nanoparticle design, predict in vivo pharmacokinetics and biodistribution, and optimize dosing strategies. Machine learning algorithms can analyze complex biological datasets, simulate nanoparticle interactions with cells and tissues, and propose design iterations that maximize efficacy while reducing adverse effects. This approach could dramatically shorten development timelines and improve reproducibility in nanomedicine.

Hybrid nanocarriers, combining organic and inorganic materials, are emerging as versatile platforms capable of performing multiple functions simultaneously, including drug delivery, imaging, and real-time monitoring of therapeutic response. Such multifunctional systems are particularly promising for complex diseases where conventional therapies fail, such as heterogeneous tumors, neurodegenerative disorders, and multidrug-resistant infections. In addition, multi-drug delivery systems and multi-stimuli-responsive nanoparticles are being developed to overcome barriers such as variable tumor microenvironments, biological heterogeneity, and dynamic physiological conditions, enabling precise spatiotemporal control over therapeutic release. The convergence of materials science, biotechnology, and engineering is expected to transform nanomedicine into a central pillar of next-generation precision medicine. Advances in biodegradable and biocompatible materials, coupled with innovations in smart delivery platforms, may enable safer, more efficient, and adaptive therapies. Furthermore, regulatory frameworks and manufacturing processes are evolving to accommodate these complex, multifunctional nanomedicines, paving the way for their translation from laboratory research to clinical applications. Overall, the future of nanomedicine is likely to involve intelligent, patient-tailored, and multifunctional nanotherapeutics that not only treat disease but also monitor and adapt to changing physiological conditions, redefining the landscape of personalized healthcare.

9. Conclusion

Nanomedicine has emerged as a transformative platform for targeted drug delivery, offering precise, efficient, and versatile therapeutic solutions that surpass the limitations of conventional pharmacotherapy. A diverse range of nanocarriers—including liposomes, polymeric nanoparticles, dendrimers, lipid nanoparticles, inorganic nanomaterials, and hybrid systems enables controlled, sustained, and site-specific delivery of therapeutic agents ranging from small-molecule drugs to nucleic acids and peptides. The integration of stimuli-responsive systems, such as pH-, temperature-, enzyme-, redox-, and magnetically responsive nanocarriers, further enhances spatiotemporal control over drug release, while ligand-mediated active targeting improves molecular specificity and reduces systemic toxicity.Nanomedicine has demonstrated broad and significant impact across multiple clinical domains. In oncology, nanosystems improve tumour penetration, overcome drug resistance, and facilitate combination chemo-immunotherapy. In cardiovascular medicine, nanoparticles enable targeted thrombolysis and plaque imaging. Neurological applications benefit from nanosystems capable of crossing the blood–brain barrier, enabling treatment and diagnosis of neurodegenerative disorders. Nanoparticle-enabled delivery of antimicrobials and vaccines plays an important role in infectious disease management, while regenerative medicine leverages nanomaterials to enhance tissue repair, cell signalling, and scaffold biofunctionality.Despite these advances, several challenges must be addressed before widespread clinical adoption is realized. Issues such as immunogenicity, rapid clearance by the mononuclear phagocyte system, off-target accumulation, long-term toxicity, and unpredictable in vivo behaviour continue to hinder translational progress. Manufacturing scalability, reproducibility, quality control, and cost-effectiveness remain major barriers, particularly for complex multifunctional nanocarriers. Regulatory frameworks for nanomedicine are still evolving, and clearer guidelines are needed to ensure standardization across physicochemical characterization, safety evaluation, and clinical testing. Nevertheless, emerging innovations suggest a promising and sustainable trajectory for the field. Advances in biocompatible and biodegradable materials, bioinspired and biomimetic nanocarriers, and multifunctional theranostic platforms are broadening therapeutic possibilities. The integration of artificial intelligence, machine learning, and computational modelling is accelerating nanocarrier design, predicting biological interactions, and optimizing dosing and therapeutic outcomes. Personalized nanomedicine tailored to individual molecular signatures holds significant potential to enhance efficacy while minimizing adverse effects. Furthermore, the convergence of nanotechnology with gene editing, immunotherapy, and regenerative engineering is poised to unlock next-generation treatment paradigms.

References

Allen, T.M. & Cullis, P.R., 2013. *Liposomal drug delivery systems: From concept to clinical applications*. Advanced Drug Delivery Reviews, 65(1), pp.36–48.

Bobo, D., Robinson, K.J., Islam, J., Thurecht, K.J. & Corrie, S.R., 2016. *Nanoparticle-based medicines: A review of FDA-approved materials and clinical trials*. Pharmaceutical Research, 33(10), pp.2373–2387

Danhier, F., Ansorena, E., Silva, J.M., Coco, R., Le Breton, A. & Préat, V., 2012. *PLGA-based nanoparticles: An overview of biomedical applications*. Journal of Controlled Release, 161(2), pp.505–522.

Hou, X., Zaks, T., Langer, R. & Dong, Y., 2021. *Lipid nanoparticles for mRNA delivery*. Nature Reviews Materials, 6(12), pp.1078–1094.

Shi, J., Kantoff, P.W., Wooster, R. & Farokhzad, O.C., 2017. *Cancer nanomedicine: Progress, challenges and opportunities*. Nature Reviews Cancer, 17(1), pp.20–37.

Majumder, J. and Minko, T., 2021. Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery. *Expert opinion on drug delivery*, *18*(2), pp.205-227.

Rosenblum, D., Joshi, N., Tao, W., Karp, J.M. & Peer, D., 2018. *Progress and challenges towards targeted delivery of cancer therapeutics*. Nature Communications, 9(1), p.1410.

Tanaka, H., Sakurai, Y. and Akita, H., 2022. Lipid nanoparticles for mRNA delivery. *Drug Delivery System*, *37*(3), pp.237-246.

Zhao, X., Bai, J. and Yang, W., 2021. Stimuli-responsive nanocarriers for therapeutic applications in cancer. *Cancer biology & medicine*, *18*(2), pp.319-335.